Acquiring drug candidate orismilast from Leo Pharma in summer of last year in a deal valued up to DKK 1.2bn (USD 186.4m) has turned out to be a good decision for Union Therapeutics.
Last month, the company entered into a strategic collaboration and license agreement about orismilast with the Chinese company Innovent Biologics, which could end up paying Union Therapeutics up to USD 267m for the exclusive rights to the research, development and commercialization of the drug in China, Hong Kong, Macau and Taiwan. It was also recently revealed that the US Food and Drug Administration has fast-tracked the former Leo Pharma eczema candidate, which is an oral treatment for atopic dermatitis, commonly known as eczema.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.